Foghorn Therapeutics, Inc. ( (FHTX) ) has released its Q2 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform, headquartered in Cambridge, Massachusetts. The company operates in the biopharmaceutical sector, with a unique approach to drug discovery and development.